Loading…
Indoco Remedies (INDOCO)₹219.34+0.22%Pharmaceuticals
Indoco Remedies is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 63.4 against a peer median of 46.2, and ROCE of 1.0% against a peer median of 16.0%, and latest-quarter sales growth of 7.2% against a peer median of 18.2%. By market cap it is #7 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis | 2,616 | 162.2 | 3.0 | 1.6 | 0.46 | 0.0 | 2,927 | 97 | −4.3 | −352.0 | vs INDOCO |
| Fredun Pharmaceuticals | 2,507 | 55.0 | 21.1 | 15.7 | 0.80 | 0.0 | 637 | 33 | 89.9 | 85.7 | vs INDOCO |
| Sakar Healthcare | 2,284 | 53.4 | 12.0 | 10.0 | 0.13 | 0.0 | 251 | 30 | 49.9 | 119.8 | vs INDOCO |
| Sai Parenterals | 2,237 | 156.2 | 5.0 | 4.9 | 0.96 | 0.0 | 382 | 14 | 435.6 | 455.2 | vs INDOCO |
| Panacea Biotec | 2,206 | — | −2.0 | −2.4 | 0.03 | 0.0 | 641 | −7 | 19.5 | −44.3 | vs INDOCO |
| Beta Drugs | 2,089 | 39.0 | 19.0 | 18.9 | 0.11 | 0.0 | 384 | 41 | 33.0 | 58.3 | vs INDOCO |
| Indoco Remedies | 2,025 | 63.4 | 1.0 | −9.4 | 1.17 | 0.1 | 1,848 | −99 | 7.2 | — | — |
| Windlas Biotech | 2,007 | 30.8 | 16.0 | 12.2 | 0.06 | 0.6 | 906 | 66 | 18.2 | 0.0 | vs INDOCO |
| Venus Remedies | 1,941 | 15.9 | 21.0 | 15.7 | 0.02 | 0.7 | 769 | 103 | 13.3 | 30.0 | vs INDOCO |
| Syncom Formulations (India) | 1,885 | 21.6 | 27.1 | 20.2 | 0.00 | 0.5 | 488 | 76 | 7.7 | 56.3 | vs INDOCO |
| Amrutanjan Health Care | 1,502 | 26.0 | 25.0 | 18.5 | 0.00 | 1.1 | 503 | 58 | 11.0 | 6.6 | vs INDOCO |
| Peer median | 2,089 | 46.2 | 16.0 | 12.2 | 0.11 | 0.0 | 637 | 41 | 18.2 | 43.2 |
Listed companies closest to Indoco Remedies in Pharmaceuticals include Dishman Carbogen Amcis, Fredun Pharmaceuticals, Sakar Healthcare, Sai Parenterals, Panacea Biotec, Beta Drugs, Windlas Biotech, Venus Remedies.
Dishman Carbogen Amcis, with a market cap of ₹2,616 Cr.
Indoco Remedies trades at a P/E of 63.4; the median of its peer set is 46.2. A P/E above or below the median is a description, not a judgement on value.
Indoco Remedies' return on capital employed is 1.0%, below the peer median of 16.0%.